nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Embolism arterial—Epirubicin—bone cancer	0.08	0.08	CcSEcCtD
Nafarelin—Embolism arterial—Doxorubicin—bone cancer	0.074	0.074	CcSEcCtD
Nafarelin—Mucous membrane disorder—Epirubicin—bone cancer	0.0287	0.0287	CcSEcCtD
Nafarelin—Mucous membrane disorder—Doxorubicin—bone cancer	0.0265	0.0265	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Methotrexate—bone cancer	0.014	0.014	CcSEcCtD
Nafarelin—Loss of libido—Methotrexate—bone cancer	0.0133	0.0133	CcSEcCtD
Nafarelin—Liver injury—Cisplatin—bone cancer	0.0133	0.0133	CcSEcCtD
Nafarelin—Interstitial pneumonia—Methotrexate—bone cancer	0.0127	0.0127	CcSEcCtD
Nafarelin—Ascites—Epirubicin—bone cancer	0.0127	0.0127	CcSEcCtD
Nafarelin—Ascites—Doxorubicin—bone cancer	0.0117	0.0117	CcSEcCtD
Nafarelin—Deep vein thrombosis—Methotrexate—bone cancer	0.0101	0.0101	CcSEcCtD
Nafarelin—Vaginal discharge—Methotrexate—bone cancer	0.0101	0.0101	CcSEcCtD
Nafarelin—Vaginal discharge—Epirubicin—bone cancer	0.00947	0.00947	CcSEcCtD
Nafarelin—Myasthenia—Epirubicin—bone cancer	0.00916	0.00916	CcSEcCtD
Nafarelin—Vaginal discharge—Doxorubicin—bone cancer	0.00876	0.00876	CcSEcCtD
Nafarelin—Interstitial lung disease—Methotrexate—bone cancer	0.00869	0.00869	CcSEcCtD
Nafarelin—Myasthenia—Doxorubicin—bone cancer	0.00848	0.00848	CcSEcCtD
Nafarelin—Seborrhoeic dermatitis—Epirubicin—bone cancer	0.00845	0.00845	CcSEcCtD
Nafarelin—Cerebrovascular accident—Cisplatin—bone cancer	0.00831	0.00831	CcSEcCtD
Nafarelin—Pleural effusion—Methotrexate—bone cancer	0.00803	0.00803	CcSEcCtD
Nafarelin—Seborrhoeic dermatitis—Doxorubicin—bone cancer	0.00782	0.00782	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Epirubicin—bone cancer	0.00778	0.00778	CcSEcCtD
Nafarelin—Pleural effusion—Epirubicin—bone cancer	0.00752	0.00752	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Doxorubicin—bone cancer	0.0072	0.0072	CcSEcCtD
Nafarelin—Pleural effusion—Doxorubicin—bone cancer	0.00696	0.00696	CcSEcCtD
Nafarelin—Sweating increased—Cisplatin—bone cancer	0.00685	0.00685	CcSEcCtD
Nafarelin—Liver injury—Epirubicin—bone cancer	0.00684	0.00684	CcSEcCtD
Nafarelin—Oliguria—Methotrexate—bone cancer	0.00668	0.00668	CcSEcCtD
Nafarelin—Herpes simplex—Methotrexate—bone cancer	0.00668	0.00668	CcSEcCtD
Nafarelin—Breast pain—Epirubicin—bone cancer	0.0066	0.0066	CcSEcCtD
Nafarelin—Liver injury—Doxorubicin—bone cancer	0.00633	0.00633	CcSEcCtD
Nafarelin—Oliguria—Epirubicin—bone cancer	0.00625	0.00625	CcSEcCtD
Nafarelin—Herpes simplex—Epirubicin—bone cancer	0.00625	0.00625	CcSEcCtD
Nafarelin—Acute coronary syndrome—Cisplatin—bone cancer	0.00618	0.00618	CcSEcCtD
Nafarelin—Pulmonary embolism—Methotrexate—bone cancer	0.00615	0.00615	CcSEcCtD
Nafarelin—Myocardial infarction—Cisplatin—bone cancer	0.00615	0.00615	CcSEcCtD
Nafarelin—Breast pain—Doxorubicin—bone cancer	0.00611	0.00611	CcSEcCtD
Nafarelin—Conjunctivitis—Cisplatin—bone cancer	0.0061	0.0061	CcSEcCtD
Nafarelin—Cystitis noninfective—Methotrexate—bone cancer	0.00601	0.00601	CcSEcCtD
Nafarelin—Cystitis—Methotrexate—bone cancer	0.00594	0.00594	CcSEcCtD
Nafarelin—Coordination abnormal—Epirubicin—bone cancer	0.00586	0.00586	CcSEcCtD
Nafarelin—Oliguria—Doxorubicin—bone cancer	0.00578	0.00578	CcSEcCtD
Nafarelin—Herpes simplex—Doxorubicin—bone cancer	0.00578	0.00578	CcSEcCtD
Nafarelin—Pulmonary embolism—Epirubicin—bone cancer	0.00576	0.00576	CcSEcCtD
Nafarelin—Cystitis noninfective—Epirubicin—bone cancer	0.00562	0.00562	CcSEcCtD
Nafarelin—Neoplasm—Methotrexate—bone cancer	0.00556	0.00556	CcSEcCtD
Nafarelin—Bladder pain—Methotrexate—bone cancer	0.00556	0.00556	CcSEcCtD
Nafarelin—Cystitis—Epirubicin—bone cancer	0.00556	0.00556	CcSEcCtD
Nafarelin—Gynaecomastia—Methotrexate—bone cancer	0.00551	0.00551	CcSEcCtD
Nafarelin—Coordination abnormal—Doxorubicin—bone cancer	0.00543	0.00543	CcSEcCtD
Nafarelin—Pulmonary embolism—Doxorubicin—bone cancer	0.00533	0.00533	CcSEcCtD
Nafarelin—Rash maculo-papular—Epirubicin—bone cancer	0.00523	0.00523	CcSEcCtD
Nafarelin—Neoplasm—Epirubicin—bone cancer	0.00521	0.00521	CcSEcCtD
Nafarelin—Bladder pain—Epirubicin—bone cancer	0.00521	0.00521	CcSEcCtD
Nafarelin—Cystitis noninfective—Doxorubicin—bone cancer	0.0052	0.0052	CcSEcCtD
Nafarelin—Cystitis—Doxorubicin—bone cancer	0.00514	0.00514	CcSEcCtD
Nafarelin—Alopecia—Cisplatin—bone cancer	0.00498	0.00498	CcSEcCtD
Nafarelin—Malnutrition—Cisplatin—bone cancer	0.0049	0.0049	CcSEcCtD
Nafarelin—Rash maculo-papular—Doxorubicin—bone cancer	0.00484	0.00484	CcSEcCtD
Nafarelin—Bladder pain—Doxorubicin—bone cancer	0.00482	0.00482	CcSEcCtD
Nafarelin—Neoplasm—Doxorubicin—bone cancer	0.00482	0.00482	CcSEcCtD
Nafarelin—Hepatic function abnormal—Epirubicin—bone cancer	0.00478	0.00478	CcSEcCtD
Nafarelin—Eye pain—Epirubicin—bone cancer	0.00463	0.00463	CcSEcCtD
Nafarelin—Cerebrovascular accident—Methotrexate—bone cancer	0.00456	0.00456	CcSEcCtD
Nafarelin—Hot flush—Epirubicin—bone cancer	0.00447	0.00447	CcSEcCtD
Nafarelin—Increased appetite—Epirubicin—bone cancer	0.00445	0.00445	CcSEcCtD
Nafarelin—Menopausal symptoms—Epirubicin—bone cancer	0.00443	0.00443	CcSEcCtD
Nafarelin—Hepatic function abnormal—Doxorubicin—bone cancer	0.00443	0.00443	CcSEcCtD
Nafarelin—Eye pain—Doxorubicin—bone cancer	0.00428	0.00428	CcSEcCtD
Nafarelin—Cerebrovascular accident—Epirubicin—bone cancer	0.00427	0.00427	CcSEcCtD
Nafarelin—Convulsion—Cisplatin—bone cancer	0.00425	0.00425	CcSEcCtD
Nafarelin—Mood swings—Methotrexate—bone cancer	0.00423	0.00423	CcSEcCtD
Nafarelin—Myalgia—Cisplatin—bone cancer	0.00417	0.00417	CcSEcCtD
Nafarelin—Hot flush—Doxorubicin—bone cancer	0.00413	0.00413	CcSEcCtD
Nafarelin—Increased appetite—Doxorubicin—bone cancer	0.00412	0.00412	CcSEcCtD
Nafarelin—Affect lability—Epirubicin—bone cancer	0.00411	0.00411	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—bone cancer	0.0041	0.0041	CcSEcCtD
Nafarelin—Oedema—Cisplatin—bone cancer	0.004	0.004	CcSEcCtD
Nafarelin—Mood swings—Epirubicin—bone cancer	0.00396	0.00396	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—bone cancer	0.00395	0.00395	CcSEcCtD
Nafarelin—Hyperhidrosis—Cisplatin—bone cancer	0.00387	0.00387	CcSEcCtD
Nafarelin—Dry skin—Epirubicin—bone cancer	0.00383	0.00383	CcSEcCtD
Nafarelin—Anorexia—Cisplatin—bone cancer	0.00381	0.00381	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—bone cancer	0.00381	0.00381	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—bone cancer	0.0037	0.0037	CcSEcCtD
Nafarelin—Muscular weakness—Epirubicin—bone cancer	0.00369	0.00369	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—bone cancer	0.00366	0.00366	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00364	0.00364	CcSEcCtD
Nafarelin—Abdominal distension—Epirubicin—bone cancer	0.00364	0.00364	CcSEcCtD
Nafarelin—Dysuria—Methotrexate—bone cancer	0.00361	0.00361	CcSEcCtD
Nafarelin—Paraesthesia—Cisplatin—bone cancer	0.00359	0.00359	CcSEcCtD
Nafarelin—Dyspnoea—Cisplatin—bone cancer	0.00357	0.00357	CcSEcCtD
Nafarelin—Dry skin—Doxorubicin—bone cancer	0.00355	0.00355	CcSEcCtD
Nafarelin—Decreased appetite—Cisplatin—bone cancer	0.00348	0.00348	CcSEcCtD
Nafarelin—Depression—Methotrexate—bone cancer	0.00343	0.00343	CcSEcCtD
Nafarelin—Gastritis—Doxorubicin—bone cancer	0.00342	0.00342	CcSEcCtD
Nafarelin—Muscular weakness—Doxorubicin—bone cancer	0.00341	0.00341	CcSEcCtD
Nafarelin—Dysuria—Epirubicin—bone cancer	0.00338	0.00338	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—bone cancer	0.00337	0.00337	CcSEcCtD
Nafarelin—Conjunctivitis—Methotrexate—bone cancer	0.00335	0.00335	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—bone cancer	0.00329	0.00329	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—bone cancer	0.00327	0.00327	CcSEcCtD
Nafarelin—Epistaxis—Methotrexate—bone cancer	0.00325	0.00325	CcSEcCtD
Nafarelin—Conjunctivitis—Epirubicin—bone cancer	0.00313	0.00313	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—bone cancer	0.00313	0.00313	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—bone cancer	0.00304	0.00304	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—bone cancer	0.00304	0.00304	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—bone cancer	0.00302	0.00302	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—bone cancer	0.00302	0.00302	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—bone cancer	0.0029	0.0029	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—bone cancer	0.0029	0.0029	CcSEcCtD
Nafarelin—Asthenia—Cisplatin—bone cancer	0.00287	0.00287	CcSEcCtD
Nafarelin—Epistaxis—Doxorubicin—bone cancer	0.00281	0.00281	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—bone cancer	0.0028	0.0028	CcSEcCtD
Nafarelin—Diarrhoea—Cisplatin—bone cancer	0.00274	0.00274	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—bone cancer	0.00273	0.00273	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—bone cancer	0.00271	0.00271	CcSEcCtD
Nafarelin—Malnutrition—Methotrexate—bone cancer	0.00269	0.00269	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—bone cancer	0.00268	0.00268	CcSEcCtD
Nafarelin—Dysgeusia—Methotrexate—bone cancer	0.00263	0.00263	CcSEcCtD
Nafarelin—Alopecia—Epirubicin—bone cancer	0.00256	0.00256	CcSEcCtD
Nafarelin—Vomiting—Cisplatin—bone cancer	0.00254	0.00254	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—bone cancer	0.00253	0.00253	CcSEcCtD
Nafarelin—Rash—Cisplatin—bone cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Dermatitis—Cisplatin—bone cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—bone cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Tension—Epirubicin—bone cancer	0.00247	0.00247	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—bone cancer	0.00247	0.00247	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Nafarelin—Vertigo—Methotrexate—bone cancer	0.00242	0.00242	CcSEcCtD
Nafarelin—Nausea—Cisplatin—bone cancer	0.00238	0.00238	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—bone cancer	0.00236	0.00236	CcSEcCtD
Nafarelin—Mental disorder—Doxorubicin—bone cancer	0.00234	0.00234	CcSEcCtD
Nafarelin—Convulsion—Methotrexate—bone cancer	0.00233	0.00233	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Nafarelin—Chest pain—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Nafarelin—Tension—Doxorubicin—bone cancer	0.00229	0.00229	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—bone cancer	0.00228	0.00228	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Nafarelin—Palpitations—Epirubicin—bone cancer	0.00222	0.00222	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—bone cancer	0.00218	0.00218	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Nafarelin—Hyperhidrosis—Methotrexate—bone cancer	0.00212	0.00212	CcSEcCtD
Nafarelin—Vertigo—Doxorubicin—bone cancer	0.00209	0.00209	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—bone cancer	0.00209	0.00209	CcSEcCtD
Nafarelin—Palpitations—Doxorubicin—bone cancer	0.00206	0.00206	CcSEcCtD
Nafarelin—Oedema—Epirubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Nafarelin—Shock—Epirubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.002	0.002	CcSEcCtD
Nafarelin—Hyperhidrosis—Epirubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—bone cancer	0.00199	0.00199	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Nafarelin—Paraesthesia—Methotrexate—bone cancer	0.00197	0.00197	CcSEcCtD
Nafarelin—Anorexia—Epirubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—bone cancer	0.00196	0.00196	CcSEcCtD
Nafarelin—Decreased appetite—Methotrexate—bone cancer	0.00191	0.00191	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—bone cancer	0.0019	0.0019	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Nafarelin—Shock—Doxorubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—bone cancer	0.00186	0.00186	CcSEcCtD
Nafarelin—Paraesthesia—Epirubicin—bone cancer	0.00184	0.00184	CcSEcCtD
Nafarelin—Hyperhidrosis—Doxorubicin—bone cancer	0.00184	0.00184	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—bone cancer	0.00181	0.00181	CcSEcCtD
Nafarelin—Decreased appetite—Epirubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Nafarelin—Constipation—Epirubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Nafarelin—Urticaria—Methotrexate—bone cancer	0.00174	0.00174	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00173	0.00173	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—bone cancer	0.00171	0.00171	CcSEcCtD
Nafarelin—Dyspnoea—Doxorubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Nafarelin—Decreased appetite—Doxorubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Nafarelin—Urticaria—Epirubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Nafarelin—Asthenia—Methotrexate—bone cancer	0.00158	0.00158	CcSEcCtD
Nafarelin—Pruritus—Methotrexate—bone cancer	0.00155	0.00155	CcSEcCtD
Nafarelin—Urticaria—Doxorubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Nafarelin—Diarrhoea—Methotrexate—bone cancer	0.0015	0.0015	CcSEcCtD
Nafarelin—Asthenia—Epirubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Nafarelin—Pruritus—Epirubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Nafarelin—Dizziness—Methotrexate—bone cancer	0.00145	0.00145	CcSEcCtD
Nafarelin—Diarrhoea—Epirubicin—bone cancer	0.00141	0.00141	CcSEcCtD
Nafarelin—Vomiting—Methotrexate—bone cancer	0.0014	0.0014	CcSEcCtD
Nafarelin—Rash—Methotrexate—bone cancer	0.00138	0.00138	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—bone cancer	0.00138	0.00138	CcSEcCtD
Nafarelin—Headache—Methotrexate—bone cancer	0.00138	0.00138	CcSEcCtD
Nafarelin—Asthenia—Doxorubicin—bone cancer	0.00136	0.00136	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—bone cancer	0.00136	0.00136	CcSEcCtD
Nafarelin—Pruritus—Doxorubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Nafarelin—Vomiting—Epirubicin—bone cancer	0.00131	0.00131	CcSEcCtD
Nafarelin—Nausea—Methotrexate—bone cancer	0.0013	0.0013	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Nafarelin—Rash—Epirubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—bone cancer	0.00129	0.00129	CcSEcCtD
Nafarelin—Headache—Epirubicin—bone cancer	0.00129	0.00129	CcSEcCtD
Nafarelin—Dizziness—Doxorubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Nafarelin—Nausea—Epirubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Nafarelin—Vomiting—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Nafarelin—Rash—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Nafarelin—Headache—Doxorubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Nafarelin—Nausea—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
